OpGen Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OpGen stock.
View analyst ratings for OpGen or view top-rated stocks.

3 brokers have issued 12-month target prices for OpGen's stock. Their OPGN stock forecasts range from $1.25 to $3.00. On average, they predict OpGen's stock price to reach $2.13 in the next twelve months. This suggests a possible upside of 291.3% from the stock's current price.
View analysts' price targets for OpGen or view top-rated stocks among Wall Street analysts.

OpGen's stock was trading at $1.00 at the beginning of the year. Since then, OPGN shares have decreased by 45.7% and is now trading at $0.5431.
View the best growth stocks for 2022 here.

OpGen is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for OpGen.

OpGen, Inc. (NASDAQ:OPGN) released its earnings results on Thursday, May, 12th. The medical research company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The medical research company earned $0.47 million during the quarter, compared to the consensus estimate of $1.05 million. OpGen had a negative trailing twelve-month return on equity of 72.67% and a negative net margin of 680.36%.
View OpGen's earnings history.

OpGen's stock reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

Some companies that are related to OpGen include Enzo Biochem (ENZ), Exagen (XGN), Sera Prognostics (SERA), Centogene (CNTG), Psychemedics (PMD), Vyant Bio (VYNT), Biocept (BIOC), American Shared Hospital Services (AMS), PharmChem (PCHM), CannLabs (CANL), CBA Florida (CBAI), Aclarion (ACON), AnPac Bio-Medical Science (ANPC), Zicix (ZICX) and PotNetwork (POTN).
View all of OPGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

(OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

OpGen's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.88%), Renaissance Technologies LLC (2.43%), GSA Capital Partners LLP (0.21%) and Arete Wealth Advisors LLC (0.18%). Company insiders that own OpGen stock include Evan/ Fa Jones, Johannes Bacher, NV In Liquidation Curetis and Oliver Schacht.
View institutional ownership trends for OpGen.

OPGN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Vanguard Group Inc..
View insider buying and selling activity for OpGen or view top insider-selling stocks.

OPGN stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, and Arete Wealth Advisors LLC. Company insiders that have bought OpGen stock in the last two years include Johannes Bacher, and Oliver Schacht.
View insider buying and selling activity for OpGen or or view top insider-buying stocks.

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPGN stock can currently be purchased for approximately $0.54.

OpGen (NASDAQ:OPGN) has a market capitalization of $25.29 million and generates $4.31 million in revenue each year. The medical research company earns $-34.81 million in net income (profit) each year or ($0.85) on an earnings per share basis.

OpGen employs 91 workers across the globe.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The official website for OpGen is www.opgen.com. The medical research company can be reached via phone at (240) 813-1260, via email at [email protected], or via fax at 301-869-9684.